Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer

Published:2013-10-27 Issue:4 Volume:4 Page:440-448
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Sun Yan¹,Wang Jin Wan¹,Liu Yong Yu²,Yu Qi Tao³,Zhang Yi Ping⁴,Li Kai⁵,Xu Li Yan⁶,Luo Su Xia⁷,Qin Feng Zhan⁸,Chen Zheng Tang⁹,Liu Wen Chao¹⁰,Zhou Qing Hua¹¹,Chen Qiang¹²,Nan Ke Jun¹³,Liu Xiao Qing¹⁴,Liu Wei¹⁵,Liang Hou Jie¹⁶,Lu Hui Shan¹⁷,Wang Xiu Wen¹⁸,Wang Jie Jun¹⁹,Song Shu Ping²⁰,Tu Yuan Rong²¹,Zhou Jing Min²²,Li Wei Lian²³,Yao Chen²⁴,

Affiliation:

1. Cancer Hospital; Chinese Academy of Medical Sciences; Beijing China

2. Liaoning Provincial Cancer Hospital; Shenyang China

3. Cancer Hospital; Guangxi Medical University; Nanning Guangxi China

4. Zhejiang Provincial Cancer Hospital; Hengzhou China

5. Tianjin Cancer Hospital; Tianjin China

6. Thoracic Tumor Hospital; Beijing China

7. Henan Provincial Cancer Hospital; Zhengzhou China

8. Anhai Provincial Cancer Hospital; Hefei China

9. Xianqiao Hospital; 3rd PLA Medical University; Chongqing China

10. Xijing Hospital; 4th PLA Medical University; Xi'an China

11. Huaxi Hospital; Sichun University; Chengdu China

12. Fujian Medical University Cancer Hospital; Fuzhou China

13. First Hospital of Xian Communication University; Xian China

14. 307 Hospital; Chinese Academy of Military Medical Sciences; Beijing China

15. Hebei Provincial Cancer Hospital; Shijiazhuang China

16. Xinan Hospital; 3rd PLA Medical University; Chongqing China

17. Fujian Medical University Union Hospital; Fuzhou China

18. Qilu Hospital; Shandong University; Jinan China

19. Changzheng Hospital; 2nd PLA Medical University; Shanghai China

20. Shandong Provincial Cancer Hospital; Jinan China

21. Fujian Medical University 1st Hospital; Fuzhou China

22. Tianjin Chest Hospital; Tianjin China

23. Tianjin 2nd Hospital; Tianjin China

24. Peking University First Hospital; Beijing China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1759-7714.12050/fullpdf

Reference56 articles.

1. State of the art: lung cancer in China;Houwen;Ann Thorac Cardiovasc Surg,2003

2. Yao M Death caused by lung cancer soars in China http://news.xinhuanet.com/english/2008-04/29/content_8074947.htm

3. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer;Scagliotti;J Clin Oncol,2002

4. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients;Le Chevalier;J Clin Oncal,1994

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A meta-analysis of recombinant human endostatin combined with NP regimen for treating non-small cell lung cancer;Medicine;2024-05-24

2. The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer;Investigational New Drugs;2024-05-03

3. Impact of Anti-angiogenic Drugs on Severity of COVID-19 in Patients with Non-Small Cell Lung Cancer;Technology in Cancer Research & Treatment;2024-01

4. Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status;Medical Oncology;2023-12-21

5. The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer;2023-11-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3